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Epilepsy is among the most common serious neurological disorders and affects around
50 million people worldwide, 80% of which live in developing countries. Despite the
introduction of several new Anti-Epileptic Drugs (AEDs) in the last two decades, one
third of treated patients have seizures refractory to pharmacotherapy. This highlights
the need to develop new treatments with drugs targeting alternative seizure-induction
mechanisms. Traditional medicine (TM) is used for the treatment of epilepsy in many
developing countries and could constitute an affordable and accessible alternative
to AEDs, but a lack of pre-clinical and clinical testing has so far prevented its
wider acceptance worldwide. In this study we used Drosophila melanogaster paralytic
bangsensitive (parabss)mutants as a model for epileptic seizure screening and tested, for the
first time, the anti-seizure effect of a non-commercial AED. We evaluated the effect of the
African custard-apple, Annona senegalensis, which is commonly used as a TM for the
treatment of epilepsy in rural Africa, and compared it with the classical AED phenytoin.
Our results showed that a stem bark extract from A. senegalensis was significantly more
effective than a leaf extract and similar to phenytoin in the prevention and control of
seizure-like behavior. These results support that Drosophila constitutes a robust animal
model for the screening of TMwith potential value for the treatment of intractable epilepsy.
Keywords: Annona senegalensis, bang sensitive, Drosophila melanogaster, epilepsy, parabss, phenytoin,
seizure, eas2F
INTRODUCTION
Epilepsy is among the most common serious neurological disorders and affects around 50 million
people worldwide, with 80% of them living in developing countries (1–4). Epilepsy can cause
frequent seizures, which are brief episodes of involuntary shaking involving part of or the entire
body, and are sometimes accompanied by a loss of consciousness. Seizures can vary in intensity
from brief lapses of attention or muscle jerks, to severe and prolonged convulsions. They can also
vary in frequency, from less than one per year to several per day.
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These episodes are triggered by hyper-excitation and/or
abnormal synchronization of activity across neuronal circuits
(5). The causes of epilepsy are attributed to acquired vs.
genetic factors. Acquired epilepsy, such as those resulting from
trauma, stroke, neoplasm, infection, congenital malformations,
birth anoxia and autoimmune, represent slightly more than a
quarter of the cases. Epilepsy with complex inheritance, ranging
from mono-gene mutations to the presence of modifiers and
susceptibility alleles has emerged as the main causes of idiopathic
epilepsy (6). Mutations in channels, that determine cellular
excitability, have been associated with a wide range of epilepsies
(5, 7). Amongst them is the sodium channel SNC1A, the human
ortholog of the parabss gene of Drosophila melanogaster, with
over 600 different mutations found in patients (8). Links to
other ionic channels (e.g., voltage-gated sodium channel a2 gene
subunit SCN2A), receptors (e.g., the N-methyl-D-aspartate-type
glutamate receptor NR2A subunit GRIN2A), synaptic proteins
(e.g., PRRT2 synaptic release) and brain development pathways
(e.g., mTOR) have also been proposed. Anti-epileptic drugs
(AEDs) mechanism of action aims to control neuronal hyper-
excitation by modifying ion channels functioning (8). Recent
studies in both developed and developing countries have shown
that up to 70% of epilepsy patients can be successfully treated
(i.e., their seizures completely controlled) with AEDs (9, 10). But
these drugs produce undesired secondary effects and in 30% of
patients they are ineffective, highlighting the need to develop
new alternative treatments (9, 10) aimed at alternative cellular
mechanisms acting to stabilize neuronal activity.
In many developing countries, particularly in Africa and Asia,
phenobarbital is the most commonly first-line prescribed AED
as recommended by the World Health Organization (WHO)
(7, 11–13), and this is likely because the other proven AEDs
phenytoin, carbamazepine, and valproate are up to 5, 15, and
20 times more expensive, respectively (14–16). Despite the fact
that access to medicines can cost as little as US$5 per year, three
quarters of patients with epilepsy have no access to treatment (1).
The availability and accessibility of Traditional Medicine (TM)
means that it plays an important role in meeting the demands
of primary health care. This was recognized by the 2008 WHO
Congress on Traditional Medicine in Beijing (17), which resolved
to promote the wider role of TM in worldwide health care and
declared that TM should be “further developed based on research
and innovation” (17).
The wild African custard-apple, Annona senegalensis
(Magnoliales: Annonaceae) is commonly found in savannas
throughout tropical Africa. Also known as soursop, dorgot
(Wolof) and sunkungo (Mandinka), a decoction of its leaves
and roots is used by rural African communities as a TM for
the treatment of seizures, suggesting that the preparation
has anticonvulsant and/or sedative properties (18). Studies
have shown that extractions from root or stem have mild
anticonvulsant properties on chemically induced seizures in
rodents, supporting a possible role of this TM in the treatment of
epilepsy (19–24). These experiments are very promising, but the
screening of drugs in rodents is too costly to test the majority of
ethnobiologically important candidates. Furthermore, follow-up
studies investigating the pharmacological properties of novel
drug candidates are intricate and even more expensive. There
is therefore a need to develop a reliable, cost-effective and high
throughput method for the screening of TMs with apparent
anti-seizure properties that could be implemented prior to
testing in animal models and clinical trials.
Adult Drosophila flies represent a genetically accessible and
behaviorally tractable model for the study of seizures (25–27).
Its strength resides in the high evolutionary conservation of
most molecules controlling neural function (28). In particular,
ion channels and synaptic transmission machinery proteins are
largely comparable (29). Drosophila and humans also share
several similarities in seizure phenotype thereof: (i) all individuals
have a seizure threshold; (ii) seizure susceptibility can be
modulated by genetic mutations; (iii) seizure activity threshold
is increased by a previous electroconvulsive shock treatment;
(iv) seizure activity spreads through the central nervous system
(CNS) along particular pathways; (v) there is a spatial segregation
of seizure activity into particular regions of the CNS; and
(vi) seizure phenotypes in flies can be ameliorated by several
AEDs used in humans including sodium valproate, phenytoin,
gabapentin, and potassium bromide (25).
Furthermore, because Drosophila presents little gene
redundancy, it offers a unique opportunity to study human
mutated genes in an animal model (30, 31). Using CRISPR/Cas9
(32) it is easy to generate knock-in mutants where the
endogenous copy of the gene is replaced by a mutated version of
the human homolog, and these flies can then be used for drug
testing to reveal behavioral, physiological and molecular effects
(30, 31).
In this study we evaluated, for the first time, the effect
of a non-commercially available drug for the treatment of
seizure in Drosophila adult flies. We tested the hypothesis that
A. senegalensis leaf and stem bark extracts affect the seizure
patterns present in parabss mutant adult flies (33, 34). We
showed that A. senegalensis stem bark extract was significantly
more effective than a leaf extract and similar to phenytoin
in the prevention and control of seizure-like behavior. These
results support that Drosophila is a robust and sensitive animal
model that can be used to screen pharmacologically untested
compounds which, combined with centuries of transmitted
knowledge about anti-convulsant TMs, could expedite the
development of the most effective TMs into novel AEDs for
patients irresponsive to classical treatments.
MATERIALS AND METHODS
Identification and Extract Preparation of
Annona senegalensis
Annona senegalensis leaves and root barks were collected
from “Boroboro,” 5 Km from Lira Municipality along
Soroti road, Northern Uganda. Geographic coordinates
are 2.190341, 32.929115 (2011’25.2”N 32055’44.8”E). Plant
was identified/deposited at Department of Biology Mbarara
University of Science and Technology, Uganda and given a
voucher No. Moses Odur 002.
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The leaves and bark removed from stem were dried and
subjected to an aqueous extraction method at the Department
of Pharmacology laboratory (School of Health Sciences, Kampala
International University Western Campus, Ishaka-Bushenyi,
Uganda). Specifically, dry leaves and stem were grounded using
a blender to obtain 200 g of powder which was mixed with 1 l of
distilled water in a sterile conical flask. The mixture was placed
on a shaker for 72 h and then sieved to remove debris. The
remaining liquid was filtered by gravity using Whatman no. 1
filter paper. The filtrate was incubated at 35◦C for 1 week to
evaporate the water and obtain a dry powder (35). The powder
extract, approximately 10 g, was stored at 4◦C until the behavioral
experiments were performed.
A phytochemical analysis was performed on the
aqueous extracts of the leaf and stem bark at the Kampala
International University Biochemistry department lab
(Supplementary Tables 1, 2).
Drug Preparation
Given the concentration of the active compound in the aqueous
A. senegalensis extract or the effective dose was unknown,
the initial assessments were done using a high concentration
(26.66mg.ml−1). Animals treated with this extract solution
appeared healthy and showed less seizure-like behavior than
controls. We decided to expand the analysis to lower extract
concentrations. A. senegalensis leaf and bark stem extracts and
phenytoin were administered by mixing them with standard
cornmeal food, which consists of 420 g of cornmeal; 450 g of
dextrose; 90 g of yeast; 42 g of agar; 140ml of 10% Nipagin in
95% EtOH; 22ml of propionic acid and 6.4 l of water. Drug and
extract solutions were prepared fresh before each experiment.
Experimental doses are expressed as mg of compound per ml
of food. For 13.33 and 26.66mg.ml−1, the powder leaf or bark
stem extract was dissolved in distilled water in a beaker at room
temperature. Warm food (<60◦C) was then added and mixed
before aliquoting approximately 1.5ml per testing vial. For the
low concentration doses of 0.26, 1.33, and 2.67mg.ml−1 a stock
solution of 2.67mg.ml−1 was used.
For phenytoin, one 100mg tablet (Tophen; Agog Pharma Ltd,
India) was suspended in 1ml of distilled water, and 50, 250 µl
or 500 µl of drug suspension were then mixed with 5ml of
food resulting in the low and high concentrations, respectively:
phenytoin 0.909, 4.76, and 9.09 mg.ml−1.
Flies Treatment and Behavioral Analysis
Flies of the bang sensitive family, specifically bang senseless (bss1)
mutants of the paralytic gene parabss1 and easily shocked (eas2F)
were obtained fromProf Richard Baines laboratory (University of
Manchester, UK), were used (26). Oregon R (OrR) is a wildtype
strain that served as a control.
Young adult flies (6–9 days) were anesthetized by cold
exposure in a freezer (−20◦C), separated on a cold plate into
males and females and assigned to vials with 10 animals each.
The flies were then randomly assigned to the different treatments
vials, (standard cornmeal food with or without drug/extract).
Each treatment was tested in at least 3 different days with flies
from different cultures.
Flies were allowed to feed for 24 h prior to behavioral
manipulations. On the day of behavioral assessment, flies were
gently transferred into empty vials and immediatelymechanically
stimulated by placement on a bench-top vortex at maximum
speed for 10 s (36, 37). Number of flies per vial on their backs,
paralyzed, shaking or standing were recorded at 30 s intervals
for 20min. Paralyzed and shaking behaviors were recorded as
seizures, whereas fully recovered flies were defined as showing
standing behavior. Number of replicates and number of flies
tested is detailed in Figure 1 legend and in Table 1. A few flies
died before testing (sticking to the food during transfer or the
24 h drug treatment) and we had counted 1 or 2 extra flies
in a few tubes. The average number of female flies tested for
each treatment compared with the control was not different
apart for female leaf 0.27mg.ml−1 and 1.33mg.ml−1 [ANOVA
F(13, 101) = 4.20, p < 0.0001, η
2
= 0.35; Dunnett’s multiple
comparisons test p = 0.008 and p= 0.01, respectively]. No
differences were registered in males [F(13,95) = 1.65, p = 0.09,
η
2
= 0.18]. This supports that survival of flies was not affected
by drug or extract treatment condition. We aimed to have 8 tube
replicas for each extract or drug concentration but labeling errors
between male and female flies produced variability on the final
sample size.
Mean recovery time was calculated as the mean of the time it
took for each individual that showed a bang sensitive phenotype
to complete recovery. Flies that never seized were not included
and animals that had not completely recovered at the end of the
experiments were included as 1,200 s.
Sequencing of paralytic Gene
Male flies were given a vortex shock to induce seizures as
describe above. Seizing males were separated from non-seizing
males. The DNA of individual parabss and OrR flies was
extracted using microLysis plus (Clent-Life Science), part of
gene amplified using F1: TGTCAAGTGTTTATGTCTCGAGC
and R1: CAGATGTTGAACAGGGCCG and sequenced using
F2: TCCAGGAGCTTTAGTCGCC and R1 primers that allow to
amplify the region that encodes the amino acid in 1699 which is
mutated in parabss mutants (38).
Gut Content Quantification
Groups of 10 flies were fed with the extract solutions plus
0.5% (w/v) bromophenol blue salt (B5525, Sigma) for 24 h,
as in the behavioral experiments. Sub-groups of 3 flies where
homogenized in 30 µl of PBS (1x) with a plastic pestle in a 1.5ml
Eppendorf tube, centrifuged twice at 13,000 rpm for 2min (39).
Dye content of the second supernatant was quantified at 594 nm
using a NanodropOne spectrophotometer (Thermo Scientific).
The background absorbance was obtained processing groups of
flies reared in the same manner but on dye-free food. The gut
food content was calculated based on a standard curve done with
serial dilutions of 0.5% (w/v) bromophenol blue in PBS.
Seizuring Data Normalization
Seizure data for each sex was normalized independently. Mean
recovery of control flies (without extract/drug) at t= 0 (Rct0) was
considered as 0% recovery, and used to normalize recovery for
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FIGURE 1 | Effect of mechanical shock on seizuring behavior for female and male adult flies of parabss or OrR genetic background. (A) Schematic of the different
phases of seizure after a mechanical shock [modified from Parker et al. (38)]. (B) Result of parabss gene sequencing in seizuring and non-seizuring males to test for the
presence of the PHE mutation in position 1699 of the protein. All flies have the mutation. (C) Mechanical stimulation did not induce seizuring in OrR flies. parabss flies
showed high proportion of seizuring at t = 0, the percentage of flies recovered increased as a function of time. The graph shows the mean % of flies recovered ± SEM
[parabss females n = 6 (60 flies); parabss males n = 7(70 flies); OrR females n = 3 (30 flies); OrR males n = 3(30 flies)]. (D) Mean recovery time comparing males and
females parabss (Mann−WhitneyU = 667, nfemales = 51, nmales = 41, P = 0.0034 two-tailed).
each experimental condition at t = 0 (Rtit0). Therefore, recovery
normalized was calculated as Rnorm = (Rtit0–Rct0)/(100–Rct0) ×
100. Normalized values were used to calculate mean and SEM.
Statistical Analysis
All behavioral data was expressed as the mean % of flies per
experimental vial ± SEM. Mixed ANOVAs, with group (sex or
treatment) as the between-subject factor and time as the within-
subject factor, were used to analyse recovering behavior. If the
ANOVA showed a significant effect of time, drug treatment or
the interaction between time and drug treatment, we performed
a Dunnett’s post hoc test to compare between sexes and/or
drug concentrations. An ANOVA and Dunnett’s post hoc test
comparing treatments was applied to evaluate differences at t= 0.
Because the distribution of MRT is not normal (as tested with
D’Agostino & Pearson’s normality test), a Kruskal-Wallis test
followed by Dunn’s multiple comparisons test to compare the
MRT for each drug treatment to the control was done. A two-
way ANOVAwith post hocDunn’s multiple comparisons test was
performed to analyse the food intake experiment. The α level was
set at 0.05 for all analyses.
Biosecurity Statement
The animal facility, flyroom, is a secure facility with access only
granted to researchers who have had an induction to the animal
facility covering health and safety and biosecurity arrangements.
Access is through a swipe card system with approval only given
on completion of the induction. To prevent animals escaping, the
flyroom windows are sealed and the doors remain closed except
when people are coming in and out andwhenmoving equipment.
In all cases there are at least three doors between the flyroom and
the outside to further minimize the risk of animals escaping from
the facility.
RESULTS
Behavioral Characterization of parabss
Mutants
In order to evaluate the effect of A. senegalensis extracts on
seizures, we first characterized the seizure-like phenotype (from
now on referred to as seizuring) of our parabss mutant strain.
parabss is a bang-sensitive mutant, extremely sensitive to seizures
that are characterized by 6 phases (Figure 1A). In response to
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TABLE 1 | Prophylactic effect of the Drug and Extract Treatments in parabss flies.
Treatment Concentration % of recovery at t = 0 % of recovery at t = 0
parabss flies (mg.ml-1) Females Males
(Mean ± SEM) p n (# flies) (Mean ± SEM) p n (# flies)
Control 0 15.85 ± 4.71 12 (134) 53.95 ± 4.07 9 (89)
Phenytoin 0.91 66.13 ± 9.55 <0.0001 8 (71) 89.86 ± 3.28 <0.0001 8 (79)
4.76 54.67 ± 10.68 0.01 5 (56) 91.67 ± 3.33 <0.0001 8 (76)
9.09 56.13 ± 4.82 0.003 6 (59) 83.15 ± 5.12 0.001 6 (51)
A. senegalensis 0.27 34.88 ± 5.06 0.39 8 (68) 75.87 ± 3.88 0.01 8 (75)
Leaf extract 1.33 45.36 ± 4.52 0.015 9 (78) 78.7 ± 6.64 0.01 6 (57)
2.66 45.39 ± 4.17 0.25 8 (79) 66.25 ± 5.98 0.31 8 (80)
13.3 58.84 ± 7.70 0.04 8 (89) 71.94 ± 4.80 0.07 8 (77)
26.6 51.34 ± 7.96 0.006 9 (89) 76.28 ± 6.65 0.01 8 (75)
A. senegalensis 0.27 64.20 ± 10.56 <0.0001 8 (72) 86.83 ± 5.53 <0.0001 8 (78)
Stem Bark extract 1.33 71.77 ± 5.97 <0.0001 7 (62) 89.89 ± 3.61 <0.0001 7 (65)
2.66 45.39 ± 4.17 0.02 9 (88) 86.25 ± 3.75 <0.0001 8 (80)
13.3 44.42 ± 7.55 <0.0001 9 (92) 74.21 ± 6.24 0.03 8 (82)
26.6 49.09 ± 7.25 0.001 8 (78) 77.47 ± 4.97 0.005 9 (92)
The percentage of recovery of parabss flies was evaluated at t = 0, just at the end of the mechanical stimulation. ANOVAs showed effect of treatment in female [F(13,114) = 4.48,
p < 0.0001] and male flies [F(13,108) = 4.74, p < 0.0001]. Dunnett’s post hoc test comparing each treatment against the control for each sex is shown in column p. The n (# flies) column
shows the number of replicates (n) and flies tested (in brackets) per condition.
a mechanical shock, many flies become immediately paralyzed
while others have a short period of shaking accompanied by leg
twitching, abdominal muscle contractions, rapid wing flapping
and proboscis extensions before paralysis. In a fraction of
animals’ paralysis is interrupted by muscle jerks, in what has
been described as a tonic-clonic phase. Most flies recover within
10min following the mechanical shock, some of them after a
short period of recovery shaking. After 20min all animals are
capable of maintaining their standing posture and can walk or
fly (38) (Figure 1A).
The seizure phenotype observed in parabss is due to a gain of
function mutation, L1699F, in the sole fly voltage gated sodium
channel gene paralytic (38) (Figure 1B). This mutation alters
the voltage dependency of channel inactivation, making neurons
more excitable and increasing the risk of aberrant electrical
activity and seizures (38). Mutations in the human ortholog,
SCN1A, are associated with a wide spectrum of epilepsies with
over 600 mutations registered in this sole locus (8).
To induce seizures, we performed a mechanical stimulation
(10 s vortex) to parabss and wildtype OrR adult flies.We evaluated
behavioral patterns of female and male flies separately because
parabss mutation is located in the X chromosome.
Immediately after induction (t = 0), none of the 60 (10 per
vial) wildtype OrR flies evaluated showed a seizuring phenotype,
while 88± 5% of parabss females and 59± 8% of males seizuring
(Two-way ANOVA, p = 0.023; Figure 1C). As expected, after
a few seconds paralyzed, flies started to recover. Some of them
recovered their standing posture directly while others went
through a tonic-clonic phase, showing strong wing flapping
and leg shaking, before standing. Mean recovery time (MRT)
for flies showing a seizure-like phenotype at the beginning of
the experiment was longer for females (319 ± 28 s) than for
males (201 ± 20 s; Mann-Whitney test: U = 677, p = 0.0034;
Figure 1D).
A mixed ANOVA on percentage of animals recovered
(Figure 1C) showed an effect of time [time: F(40,440) = 34.03,
p < 0.001, η2 = 0.76] and sex [F(1,11) = 11.16, p = 0.007,
η
2
= 0.50], and an interaction [time X sex: F(40,440) = 3.17,
p < 0.001, η2 = 0.22]. These results showed an unexpected
sexual dimorphism in seizuring phenotype, with males being
more resistant to the initiation of seizures and recovering faster
than females if and when they showed the seizure phenotype. We
confirmed that our stock still carries the mutation described in
the literature, sequencing the paralytic gene in OrR wildtype flies
and parabss mutants. All 12 mutants, 6 of which did not seize at
t = 0, had LEU mutated to PHE in position 1699. Therefore,
despite these differences, the high penetrance of seizure-like
behavior and the reproducibility of the phenotype confirm that
parabss flies are well suited to evaluate anti-seizure properties of
candidate compounds as well as the dynamics of recovery from
seizuring and indicate that male and female behavior need to be
assessed separately.
Effect of Annona senegalensis Extracts:
Female Flies
To evaluate the effect of A. senegalensis as an anticonvulsant, we
compared the seizure-like behavior of parabss flies kept in control
food to animals treated with food mixed with aqueous extract
from leaf or stem bark of A. senegalensis. As a positive control, a
group of flies was treated with phenytoin, a commonly prescribed
AED which has already been tested in flies (36) (Figure 2). Flies
received an acute drug treatment consisting of feeding on control
or treated food for 24 h before behavioral testing. Seizure-like
behavior measured as the % of recovered animals across time
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FIGURE 2 | Effect of phenytoin and A. senegalensis leaf and stem extracts on recovery from seizures of parabss female flies. parabss flies treated with control food
showed a very low percentage of flies recovered from seizures after mechanical perturbation, which improved over time. (A) Treatment with phenytoin increased the
percentage of recovered flies at three different doses. (B) Treatment with A. senegalensis leaf extracts increased the percentage of flies recovered. (C) A. senegalensis
stem extract doses showed a greater effect than the leaf extract. (D) Dose response analysis at t = 0 for all treatments. Graphs show the mean % of flies seizuring ±
SEM (for number of replicates, flies and significance values see Table 1).
was analyzed by mixed ANOVA comparing the effect of drug and
time for female flies. An effect of time [time: F(40,4040) = 238.83,
p < 0.0001, η2 = 0.70], drug [drug: F(13,101) = 4.53, p < 0.0001,
η
2
= 0.37] and an interaction [time X treatment: F(520,4040) =
3.29, p< 0.0001, η2 = 0.30] was found in females confirming that
the treatments modified the time of recovery from seizures. We
therefore analyzed the individual effect of each drug treatment on
the seizure-like phenotype.
As expected, parabss flies kept in control food were
significantly affected by the mechanical stimulation, with
15.85 ± 9.55% of flies standing at t = 0 and a MRT of
284± 21 s (Figure 3A).
As a positive control we evaluated phenytoin, a drug known
to modulate the gating of voltage gated sodium channels (40).
Phenytoin has already been shown to diminish seizures in
parabss flies, but those tests used different concentrations to the
range used in our experiments and males and females were
analyzed together. In the present study, phenytoin significantly
improved the seizure-like phenotype of parabss females over time.
A mixed ANOVA on % of animals recovered in control vs. the
three phenytoin concentrations showed significant interaction
effects of treatment across time [time X treatment: F(120,1120)
= 5.07, p < 0.0001, η2 = 0.35] and time alone [time: F(40,120)
= 39.94, p < 0.0001, η2 = 0.59], and an effect of treatment
[F(3,28) = 3.69, p = 0.02, η
2
= 0.28; Figure 2A]. A follow-
on post hoc analysis showed a significant effect of phenytoin
at 0.91mg.ml−1 (Dunnett test: vs. control p = 0.007) but no
effect at the higher doses, 4.76 and 9.09mg.ml−1 (p > 0.3). At
4.76 and 9.09mg.ml−1 we observed that the curves of % of
recovery were below the curve of control after 480 s indicating
that parabss flies were recovering faster than the flies treated
with the higher concentrations (Figure 2A). Indeed, phenytoin
failed to shorten the MRT at 4.76 and 9.09mg.ml−1 and the
tendency was to increase it (Figure 3A), suggesting that the
higher concentrations might have a small toxic effect on the flies.
However, phenytoin had a clear prophylactic effect at t = 0. The
three concentrations increased the percentage of recovered flies
being the lower concentration the most effective (Dunnett test:
control vs. 0.91mg.ml−1 p < 0.0001; vs. 4.76mg.ml−1 p = 0.009
and vs. 9.09mg.ml−1 p = 0.003; Figure 2D and Table 1). At
these concentrations, phenytoin protected against the initiation
of seizure (Figures 2A,D, 3).
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FIGURE 3 | Mean recovery time for parabss flies treated with phenytoin and, leaf and stem bark A. senegalensis extracts. The time it took for each individual that
showed a bang sensitive phenotype to complete recovery was calculated. Flies not seizuring were not included and if a fly was still seizuring at the end of the
experiment its time was recorded as 1,200 s. Mean ± SEM is shown. (A) The MRT was significantly affected by the treatment in females (Kruskal-Wallis test H(14) =
30.21, p = 0.004). There were no differences between the control and other treatments as tested with a Dunn’s post hoc test. (B) The MRT was significantly affected
by the treatment in males (Kruskal-Wallis test H(14) = 31.04, p = 0.003). Dunn’s post hoc test showed that the control was only different with the stem bark
13.3mg.ml−1 treatment (p = 0.02). Number of males is lower because MRT measures the time to recovery of paralyzed flies, and fewer males than females where
paralyzed at t = 0.
We then analyzed the effect of A. senegalensis leaf extract
(Figures 2B,D). The five curves of animals treated with the
leaf extract showed an improvement in the percentage of
flies recovered from seizure over time. This observation was
confirmed by a mixed ANOVA on the percentage of flies
recovered, which showed significant effects of time [time:
F(40,1960) = 189.37, p < 0.0001, η
2
= 0.79], treatment [drug:
F(5,49) = 6.56, p < 0.0001, η
2
= 0.40] and their interaction [time
X drug: F(200,1960) = 3.07, p < 0.0001, η
2
= 0.24]. A follow-
on Dunnett’s post hoc analysis comparing each drug with the
control showed no effect at 0.27mg.ml−1 (p = 0.31) and a
greater time-dependent recovery in animals treated with the
leaf extract above 1.33mg.ml−1 (control vs.: 1.33mg.ml−1 p <
0.0001; 2.67mg.ml−1 p = 0.05; 13.3mg.ml−1 p = 0.002 and
26.6mg.ml−1 p = 0.001). The quantification at t = 0 showed
an improvement in the percentage of flies insensitive to seizure
depending on the concentration with a significant prophylactic
effect at 0.27, 1.33, 13.33, and 26.6mg.ml−1 (Figure 2D and
Table 1). To test if the leaf extract alleviates the seizure by
reducing their duration, we quantified the MRT. There was no
shortening of the MRT comparing the parabss control to the five
concentrations of leaf extract (Kruskal- Wallis with Dunn’s post
hoc test; Figure 3A). All together, these results indicate an anti-
seizure effect of A. senegalensis leaf extract on parabss female flies
that is mainly attributed to a prophylactic effect of the drug.
Finally, we evaluated the anti-convulsant properties of A.
senegalensis stem bark extract (Figures 2C,D). A mixed ANOVA
on percentage of flies recovered showed significant effects
of time [time: F(40,1920) = 105.02, p < 0.0001, η
2
= 0.69],
treatment [F(5,48) = 9.67, p < 0.0001, η
2
= 0.50] and of their
interaction [time X treatment: F(200,1920) = 5.05, p < 0.0001,
η
2
= 0.35]. A follow-on post hoc analysis comparing the
different concentrations to the control showed that the stem bark
extract treatment produced a very significant improvement of
the % of recovery (Dunnett test: control vs. 0.27, 1.33, 13.33,
and 26.6mg.ml−1 p < 0.0001 and 2.6mg.ml−1 p = 0.006).
Furthermore, the five concentrations of the drug showed a
significant increment of the % of flies recovered compared
to control at t = 0 (Figure 2D and Table 1). However, this
differences over time were not reflected in shorter MRTs
(Figure 3A). Meaning that if a fly has started seizing it will
recover on average at the same pace as a parabss mutant which
was not treated with the stem extract. As for the other drugs
tested, the improvement in seizure-like behavior quantified
in flies treated with the stem bark was mainly due to its
prophylactic effect.
Effect of Annona senegalensis Extracts on
Male Flies
We then evaluated the seizure phenotypes ofmales exposed to the
same treatments as females. In males under control conditions,
the percentage of flies recovered after mechanical stimulation
is significantly higher than in females (200 ± 21 s; Figure 1C)
and the MRT is significantly shorter (204 ± 19 s; Figure 3B).
Significant drug effects were therefore expected mainly at the
early time points of behavioral analysis. A mixed ANOVA on the
percentage of male flies recovered after mechanical stimulation
showed an effect of time [time: F(40,3800) = 96.55, p < 0.0001,
η
2
= 0.50], an interaction between time and treatment [time X
treatment: F(520,3800) = 108.97, p < 0.0001, η
2
= 0.32], and an




Frontiers in Neurology | www.frontiersin.org 7 January 2021 | Volume 11 | Article 606919
Dare et al. Annona senegalensis Extract Anticonvulsant Effect
FIGURE 4 | Effect of phenytoin and A. senegalensis extracts on recovery from seizures of parabss males. Mechanical stimulation of parabss control male flies induced
a seizure-like phenotype that was less penetrant than in females. The effects of phenytoin (A), A. senegalensis leaf (B) or stem extract (C) are shown. (D) Dose
response analysis at t = 0 for all treatments. Graphs show the mean % of flies seizuring ± SEM (for number of replicates, flies and significance see Table 1).
We then analyzed the behavioral effect for each drug
treatment independently. Amixed ANOVA on percentage of flies
recovered comparing phenytoin treated animals with controls
showed an effect of time [time: F(40,1080) = 30.95, p < 0.0001,
η
2
= 0.53], an interaction between time and treatment [time
X treatment: F(120,1080) = 12.40, p < 0.0001, η
2
= 0.58] and
of treatment [F(3,27) = 21.94, p < 0.0001, η
2
= 0.71]. Further
post hoc analysis showed that all three concentrations were
significantly better than the control (Dunnett: control vs. 0.91,
4.76 and 9.09mg.ml−1 of phenytoin p < 0.001; Figure 4A).
Significant behavioral differences (p < 0.001) were found at t =
0 for the three concentrations tested (Figures 4A,D and Table 1).
We did not observe differences in MRT across groups, probably
due to a low number of flies seizuring at early time points.
However, as observed in females, at 4.76 and 9.09mg.ml−1
of phenytoin, a few flies had longer MRT then in controls,
suggesting that the highest concentrations tested have a slight
toxic effect on male flies as well (Figure 3B).
We then evaluated the effect of A. senegalensis leaf extract
treatment. A mixed ANOVA on the percentage of flies recovered
showed a significant effect of time [time: F(40,1640) = 68.50,
p < 0.0001, η2 = 0.63], and a significant interaction between
time and drug treatment [time X treatment: F(200,1640) = 1.46,
p < 0.0001, η2 = 0.15], but no effect of drug alone [treatment:
F(3,29) = 1.77, p = 0.14, η
2
= 0.18; Figure 4B]. The lower effect
of the leaf extract onmales was further supported by a generalized
moremodest improvement at t= 0 (Figure 4D andTable 1). The
MRT was not significantly improved for any concentration of the
leaf extract (Figure 3B).
An effect of time, treatment and their interaction were present
after treatment with stem bark extract of A. senegalensis in males
[time: F(40,1720) = 48.57, p < 0.0001, η
2
= 0.53; treatment: F(5,43)
= 6.84, p< 0.0001, η2 = 0.44; time X treatment: F(200,1720) = 4.10,
p < 0.0001, η2 = 0.32]. A Dunnett’s post hoc analysis confirmed
the improvement in the % of recovery of the flies treated with
the stem bark extract compare to the untreated control, all
concentrations being highly significant (control vs. 0.27, 1.33,
and 26.6mg.ml−1 p < 0.0001 and vs. 2.67mg.ml−1 p = 0.001
and 13.3mg.ml−1 p= 0.002; Figure 4C). As in phenytoin treated
animals, stem bark extracts very significantly decreased the
percentage of animals seizuring at t= 0 pointing to a prophylactic
effect against the initiation of seizure-like behavior (Figure 4D
and Table 1). Furthermore, the treatment with stem bark extract
at 13.3mg.ml−1 was the only treatment to significantly decrease
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FIGURE 5 | Dose-dependent prophylactic effect of phenytoin and, leaf and stem bark A. senegalensis extracts. (A) Normalized % of recovery at t = 0 for females and
males. The concentration is in log10 scale. An ANOVA comparing the effect of the three drugs treatment was significant [F (2,199) = 15.06, p < 0.0001, η
2
= 0.13].
A post hoc Bonferroni multiple comparisons test was used to test for differences between the drugs (phenytoin vs. leaf p < 0.0001; vs. stem p = 0.35 and leaf vs.
stem p = 0.0001). No significant differences between concentrations of each drug were found, apart when comparing with the control (Tukey’s multiple comparisons
test). (B) Amount of food ingested per fly and per 24 h. A two way ANOVA showed no effect of drug [F (1,103) = 0.03, p = 0.86], no effect of concentration [F (5,103) =
1.63, p = 0.16] and no interaction [F (5,103) = 1.26, p = 0.28]. A post hoc Dunnett’s multiple comparisons test comparing the control with each treatment did not yield
any significant differences.
the MRT (p = 0.02; Figure 3B) supporting the effectiveness of
the drug.
Altogether, these results show that recovery in both female
and male flies was improved by treatments with A. senegalensis
stem and leaf extract as well as with the commonly used AED
phenytoin. To gain a better insight into the dose-response curve,
we normalized the percentage of recovery. This allowed us to
only evaluate the effect of the drug and extracts on flies seizuring
at t = 0 (now at t = 0 there is 0 ± SEM % recovery for all
treatments; Figure 5A). In this condition the sexual dimorphism
is no longer present, and we therefore pooled the data of
both sexes. The three curves are in the plateau phase and no
significant effect of concentration was found, apart for when
comparing with the control. At saturated doses, the prophylactic
effect of phenytoin is comparable to A. senegalensis stem bark
administration (p = 0.66; Figure 5A). There is a slight but
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non-significant decrease of phenytoin and stem bark effects,
suggesting that higher concentrations of these compounds may
have toxic or sedative effect. The leaf extract of A. senegalensis
showed a lower protective effect than phenytoin (p < 0.0001)
and stem bark (p = 0.0002), present at all concentrations
(Figure 5A). Differences of prophylactic effects are not explained
by differences in amount of food ingested since there were
no significant differences in gut content between treatments
(Figure 5B). The strong effect of A. senegalensis stem extract
suggests the existence of an AED compound that could offer an
alternative for the treatment of intractable epilepsy.
Effect of Annona senegalensis Extracts on
easily shocked Mutants
To test the efficacity of A. senegalensis when the molecular
cause of the hyperexcitability is other than mutations of an
ionic channel, we decided to evaluate its effect on easily shocked
mutants (eas2F), which carry a mutation in an ethanolamine
kinase which affects the phospholipid composition of neuronal
membranes (41). This bang sensitivemutant is known to improve
upon treatment with phenytoin but is partially or completely
insensitive to other drugs like carbamazeprine, ethosuximide,
and vigabactrin (36). When we tested the leaf and stem bark
extract at 2.67 and 26.6mg.ml−1 on eas2F flies, we did not observe
any improvement in their percentage of recovery (Table 2).
Rather the mutants were more paralyzed and the only significant
changes in the MRT were due to a delay in recovery (Table 2).
This experiment shows that despite the similarity in the
prophylactic effect between phenytoin and A. senegalensis extract
on parabss, it is likely that their mode of action differs.
DISCUSSION
Approximately 30 AEDs are currently approved for treatment
of patients affected by epilepsy, an aetiologically complex
and variable disease. A non-negligible percentage of epileptic
experience undesired secondary effects of these AEDs, and
30% of patients are insensitive to them altogether (9, 10),
highlighting the necessity of discovering alternative compounds
to incorporate in the design of novel therapies.
Almost all commonly prescribed AEDs were discovered by
animal screenings (40) and their mechanisms of action were
also studied in non-human species, emphasizing the importance
of animal testing for drug discovery in epilepsy. Medicinal
plant extracts have been historically used for the treatment of
various diseases, including epilepsy. The knowledge gathered and
transmitted for generations about the anti-seizure properties of
herbal TM preparations constitute a rich source of information
for the discovery of new drug candidates. However, an empirical
testing of their efficacy as AED and the pharmacological
characterization of the active compound is required. A few
hundred drugs used in TM have been tested in epilepsy animal
models but the lack of follow up clinical and pharmacological
studies places constraints on the clinical recommendation of
herbal TMs (42).
In the present study, we used a Drosophila seizure model
to test the effect of A. senegalensis extracts as an anti-seizure
treatment (25–27).We used a fly with a gain of functionmutation
in the unique voltage gated sodium channel of Drosophila
genome, parabss, which is extremely prone to seizures. parabss
mutant flies are generally accepted as a model for intractable
epilepsy due to the complexity of their seizures, including a
tonic-clonic-like phase, and their significant resistance to AED
treatments (38). A. senegalensis was used because of its strong
reputation as a TM potentially effective for the treatment of
seizures and because several studied performed in rodents
have tested its anticonvulsant properties (19–24). In these
studies, extracts of A. senegalensis were prepared with different
methods (in general with polar solvents) and from different
parts of the plant (leaf, root or stem). In all cases, an acute
treatment with the extract, via intraperitoneal injection or via oral
administration, produced a significant prophylactic effect against
seizures induced by pentylenetetrazole, picrotoxin, pilocarpin
or maximal electroshock (19–24). However, drug testing in
mammals is costly and slow, reducing the number of compounds
that can be subject to thorough analysis. Using Drosophila as a
model system offers an opportunity to overcome such limitations
and isolate active compounds in a high throughput and cost-
effective manner.
parabss flies showed a strong seizure-like phenotype
with significant differences between males and females.
Approximately 85% of females were paralyzed after the
mechanical stimulation, while only 50% of the males were.
Despite this level of seizuring been below the one described in
previous reports (36–38), the aminoacidic residue leucine in
position 1699 was mutated to Phenylalanine in our parabss stock.
This suggests that a repressor mutation in the X chromosome
might be compensating for the L1699P mutation or, less likely,
that our stock has lost an enhancer mutation that was generating
the original fully penetrant phenotype.
Alternatively, this could be a consequence of the lack
of controlled circadian synchronization in our experimental
animals. In humans, it is known that the onset of seizures and
the interictal epileptiform discharges (IED) have a tendency to
occur in specific times of the day. For example, tonic-clonic
seizures occur more frequently during sleep. This rhythmicity
is controlled by both the circadian clock and sleep-wake state
(43). In our experimental conditions, flies were inadvertently
tested at different endogenous circadian time. This factor might
have influenced the seizure threshold across animals, generating
heterogeneity in the penetrance of the seizure phenotype. In this
scenario the known behavioral differences in the rest-activity
cycles between females (more active) and males might have
resulted in the sexual dimorphism observed (44). It would be
interesting to take advantage of the knowledge of circadian
rhythms in Drosophila to further investigate the molecular and
cellular mechanisms underlying the circadian and vigilance
regulation of seizures.
Although presenting lower levels of seizuring than in the
literature and sexual differences in phenotype penetrance, both
sexes showed a measurable level of paralysis and recovered
gradually, so they could be used to test the anti-seizure effect
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% of recovery at t = 0
Females Males
(Mean ± SEM) p n (# flies) (Mean ± SEM) p n (# flies)
Control 0 6.73 ± 3.09 13 (115) 0.63 ± 0.63 16 (137)
A. senegalensis 2.67 0 ns 8 (73) 1.25 ± 1.25 ns 8 (69)
Leaf extract 26.6 0 ns 6 (54) 0 ns 8 (75)
A. senegalensis 2.67 0 ns 8 (73) 1.39 ± 1.39 ns 8 (73)
Stem Bark extract 26.6 1.39 ± 1.39 ns 10 (92) 4.26 ± 2.11 ns 8 (74)
Mean recovery time
Control 0 50.86 ± 2.73 105 79.17 ± 3.27 133
A. senegalensis 2.66 59.59 ± 3.58 ns 73 83.33 ± 4.83 ns 72
Leaf extract 26.6 70.00 ± 3.72 <0.001 54 81.20 ± 4.85 ns 92
A. senegalensis 2.66 58.29 ± 3.39 ns 70 77.67 ± 4.68 ns 73
Stem Bark extract 26.6 66.49 ± 3.71 0.001 74 70.87 ± 4.55 ns 69
Percentage of recovery at t =0. Kruskal-Wallis tests comparing each treatment were non-significant for females [χ2(5) = 6.45, p = 0.17] and males [χ
2
(5) = 7.66, p = 0.1]. The result of
Dunn’s post hoc test comparing each treatment against the control for each sex is included in the p column of the table. The n (# flies) column shows the number of replicates (n) and
flies tested for each treatment.
Mean recovery time. Kruskal-Wallis test comparing each treatment showed a significant effect for females [χ2(5) = 23.98, p < 0.0001] but not for males [χ
2
(5) = 4.34, p = 0.36]. The
result of Dunn’s post hoc test comparing each treatment against the control for each sex is included in the p column of the table. The number of flies seizuring at t = 0 is shown in
column n.
of A. senegalensis. Our experimental design was therefore suited
to analyse the overall effect of drug treatments, from seizure
induction to complete recovery. More precisely, we evaluated (1)
the prophylactic effect against seizure induction and (2) the effect
on recovery dynamics. We compared the effect of A. senegalensis
extracts, to the commonly used AED phenytoin. Phenytoin was
chosen as our positive control since its anti-convulsion properties
have been documented in flies before. When administered
chronically and at low doses (0.03–0.3mg.ml−1) it induced a
decrease in MRT in a mixed population of males and females
parabss (36).
In our experimental conditions (24 h drug exposure in
the food, 0.91, 4.76 and 9.09mg.ml−1), phenytoin produced
the expected improvement on seizuring phenotype. This was
characterized by a clear prophylactic effect of all three doses,
with fewer male or female flies showing seizures compare to
controls at the beginning of the experiment (t = 0). The MRT
was not improved at any concentration but this might be due
to a slight toxic effect of phenytoin at 4.76 and 9.09mg.ml−1.
At this concentration the MRT slightly increased and a few flies
remained paralyzed for the entire duration of the experiment
(1,200 s), a phenotype not observed in parabss mutants.
The treatment with A. senegalensis stem bark extract
effectively improved the seizure-like phenotype. At the lower
doses (below 2.67mg.ml−1) approximately 60% of the flies did
not seizure at t = 0, showing a similar effect to the one
quantified with phenytoin. We could not quantify a decrease in
the MRT indicating that once the seizure has started the drug
barely ameliorates the symptoms. In comparison, treatments
withA. senegalensis leaf extracts were less effective than stem bark
extracts, suggesting that the active compound of the plant is most
concentrated in the stem bark.
These findings are significant because they lay the bases for
future studies aiming to discover the active chemical compound
present in A. senegalensis stem bark extract. In that direction,
it would be possible to use this experimental approach to test
the anti-seizure effect of samples coming from an extensive
sub-fractioning of stem bark extracts. This would allow further
purification and identification of the active compound.
One such simple sub-fractioning experiment was performed
from A. senegalensis roots. It identified a putative candidate
belonging to the diterpenoid family, Kar-16a-19oic acid, that
showed promising sedative and anti-seizure properties in rodents
(21). The candidate compound was enriched in an ethyl-acetate
fraction and showed an acute toxicity in mice of LD50 = 2154
mg/kg compared to LD50 = 150mg/kg for phenytoin (pubchem).
Toxicity of an aqueous extract, like the one used in our
experiments, in mice is lower, LD50 > 5,000 mg/kg (45), which
would make it ideal for its clinical recommendation as a TM
(9). This and other candidates could be further tested using the
present animal model.
The difference in prophylactic effect observed on parabss
and eas2F mutant flies gives an indication regarding the
possible mechanism of action of A. senegalensis extract. It
has already been shown that the percentage of eas2F mutants
seizuring improves when treated with phenytoin (36) but that
the mutants are resistant to treatment with several AEDs
(36): carbamazepine a sodium channel blocker; ethosuximide
that blocks T-type calcium channels, and may include effects
on other classes of ion channel; vigabatrin that increases
GABA in the brain blocking the activity of the gamma-
aminobutyric acid aminotransferase and gabapentin which has
recently been shown to selectively inhibit calcium channels
containing the a2d-1 subunit (46). Because A. senegalensis
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improves the phenotype of parabss but not eas2F , it is likely
that the active compound acts via a mechanism different than
phenytoin, not acting on voltage gated sodium channels (40).
On the other hand, an anticonvulsant effect of A. senegalensis
leaf extract was shown on pentylenetetrazol (PTZ) induces
convulsions in mice (19). PTZ antagonizes GABAA receptor Cl–
channel complex (19) attenuating GABA-dependent inhibition
and inducing seizures. It is possible that A. senegalensis effect
is partially due to enhancement of GABAergic pathways. If
this were the case, a high concentration of the plant extract
could produce a sedative effect and induce more paralysis as
observed when testing eas2F . Ultimately, experiments to test
the mechanism of action of A. senegalensis extract should
be performed.
The simplicity, reproducibility, potential high throughput
and low cost of the testing method reported here constitutes
an ideal setup to isolate the active anti-seizure compound
present in A. senegalensis and potentially other TMs. Molecules
controlling the development and function of the nervous system
(28, 29) in Drosophila and humans present high structural
and functional conservation. Drosophila could provide an
early neurophysiological characterization of the mechanisms of
action of new candidate compounds with potential translational
anti-seizure effects (25–27, 47, 48). Specific neurons whose
neurotransmitter identity and connectivity are known could
be patch-clamped in parabss and the effect of the drug tested
(49). The contribution of inherited or de novo mutations in
the etiology of epilepsy, including focal epilepsy (6, 50), is
growing. Sodium channels, that play a crucial function for
cellular excitability, have been associated with a wide range of
epilepsies (5). Amongst them is SNC1A, the human ortholog
of parabss, with over 600 different mutations found in patients
(8). Links to other ionic channels, receptors synaptic proteins
and brain development pathways have also been proposed.
The genetic malleability of Drosophila, where specific gene
mutations can easily be generated, strengthens its validity
for screening and early characterization of neural mechanism
underlying hyperexcitability.
Screening TMs in several distinct Drosophila seizuring
mutants will most likely help isolating new compounds
for intractable epilepsy. This is exemplified by the lack of
prophylactic effect induced by A. senegalensis extract on eas2F
mutants, which are insensitive to many EADs but might benefit
from new drugs (36).
However, fruit flies and humans also show fundamental
differences that need to be taken into consideration when
interpreting screening results. From a circuit point to view, the
fly brain is much simpler with no cortical and subcortical regions
where most focal source of seizure are located in humans. From
the aetiological perspective, the causes of epilepsy in humans
are varied ranging from inherited (genetic) to acquire through
brain injury (e.g., prenatal or perinatal causes, severe head or
brain injury, stroke, infections) (11). Treatment with AEDs
aims to re-balance neuronal activity but fly models of epilepsy
might fail to capture the full spectrum of neural and brain
dysfunctions. Limited behavioral phenotypes in flies suggest that
only seizure resembling the “grand mal” with strong spams
and muscular manifestations could be studied. More complex
or subtle cognitive and emotional aspects of epilepsies are not
accessible in flies. Finally, absence of a proper brain blood barrier,
an open hemolymph circulation and the distinctive renal system
of Drosophila compromises translation of pharmacokinetics and
toxicity data to humans.
Ultimately, pre-clinical research in different animal models
complemented with clinical trials in humans will be essential in
establishing effectivity and safety profiles for TM compounds for
the treatment of epilepsy.
In conclusion, our work is important because it confirms
how powerful Drosophila is as a model system for screening of
putative new AEDs. Regardless of the fact that there was little
information about how to prepare the plant extract, we did not
know the identity of the active compound, its effective dose,
pharmacokinetic, or toxicity in flies, we were able to find a strong
anti-seizure effect of A. senegalensis stem bark extracts on parabss
flies. This method could be used for high throughput screening
of many TM with suspected anti-convulsion properties, hence
offering a robust platform for the identification and isolation
of novel AEDs that could be the basis of new treatments for
intractable epilepsy.
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